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Abstract
Background: Testing for viral DNA in neonatal blood dried on paper (DBS) has proved a valid
means of diagnosing congenital CMV infection with both clinical and epidemiological relevance. To
assess the quality of the detection of CMV-DNA on DBS in laboratories performing this test a
proficiency panel consisting of nine samples with two blood spots on each filter paper was
produced and distributed. Six samples were derived from whole blood, negative for CMV DNA
and antibody, and spiked with cell-grown CMV Towne in various concentrations (7.3 × 102 – 9.6 ×
105 copies/ml), one was a CMV positive clinical specimen (3.9 × 106 copies/ml), and two samples
were CMV-negative whole blood.
Results: The 27 responding laboratories from 14 countries submitted 33 datasets obtained by
means of conventional PCR (n = 5) or real-time PCR (n = 28) technologies. A correct positive
result was reported in at least 91% of datasets in samples with a viral load of 8.8 × 104 copies/ml
or higher. However only 59% and 12% identified the 9.4 × 103 and 7.3 × 102 copies/ml samples,
respectively, correctly as positive. False positive results were reported by 9% of laboratories and
in 11% of datasets.
Conclusion: These results indicate a clear need for improvement of methods as sensitivity and
false-positivity still appear to be a major problem in a considerable number of laboratories.
Background
Congenital CMV infection is the most widespread con-
genital infection in humans and is a major cause of neu-
rological damages such as hearing loss, visual impairment
and mental retardation in children. Diagnosis of congen-
ital CMV infection requires laboratory testing done on
samples collected in the first three weeks of life. Testing
for CMV-DNA in neonatal blood collected on filter-paper
(dried blood spot, DBS) has proved a valid means of diag-
nosis with both clinical and epidemiological relevance.
Applications of this assay range from diagnosis in the neo-
natal period as an alternative to the conventional urine
culture method to the unique quality of ascertaining
whether damages arising during infancy are due to con-
genital infection [1,2].
Most laboratories use an in-house developed assay for
detection of CMV-DNA in DBS. However, no interna-
tional standard is available and previous external quality
assessment studies have shown that the quality of nucleic
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acid amplification methods such as PCR varies considera-
bly between laboratories [3,4]. Therefore a quality assess-
ment study for the detection of CMV-DNA on DBS was
recommended by the European Congenital CMV Initia-
tive (ECCI) group and was organised by QCMD (Quality
Control for Molecular Diagnostics). We report the results
of the CMV-DNA amplification assays performed on a
panel consisting of DBS with decreasing viral DNA con-
tent which was prepared for the study.
Results and discussion
Thirty-three laboratories from 13 European countries and
two from South Africa participated in the study. Twenty-
seven laboratories submitted their results for a total of 33
datasets, as two respondents submitted two datasets and
two sent three datasets each.
Few data on the characteristics of the participating labora-
tories are available as only a limited number of laborato-
ries returned a completely filled out technical
questionnaire. Thirteen of the 15 respondents operated in
a University Hospital setting and 10 of the 15 were accred-
ited. Five labs reported to have some experience in DBS
testing. However, the annual number of specimens exam-
ined was usually small (<10–30 per year).
The molecular analysis was performed by means of in-
house nested-PCR (n = 5) or real-time PCR (n = 28) tech-
nologies. Five datasets from three laboratories were
obtained by means of commercial real-time PCR. Nucleic
acid extraction was performed by means of commercial
kits in 26 of 30 datasets. Only qualitative PCR results will
be discussed as no more than five laboratories reported
quantitative results of their real-time PCR assays.
Correct positive results on samples with a viral load of 8.8
× 104  copies/ml or higher were reported in ≥ 30/33
(90.7%) of datasets. However, performance on samples
with lower viral loads dropped rapidly, with only 59%
and 12% of correct positive results in samples with 9.4 ×
103 and 7.3 × 102 copies/ml, respectively. Three laborato-
ries reported a total of five false positive results (Table 1).
The same three labs were among the six that reported pos-
itive results for the 7.3 × 102 copies/ml samples but one of
them was unable to detect the 9.4 × 103 copies/ml sam-
ples.
Thus, the 9.4 × 103 copies/ml DNA concentration in the
spiked whole blood represented the 50% sensitivity
threshold of the tests.
The panel was designed primarily to assess sensitivity, as
this was regarded as the overriding problem in the detec-
tion of CMV-DNA on dried blood spots. To allow compar-
ison of the performance of laboratories, results were
scored using a simple scoring system assigning two points
for a correct result and zero points if the result was not cor-
rect. None of the datasets reported a maximum score of 18
Table 1: Composition of the panel and results of the pre-release testing and of the study
Correct qualitative results
PCR
Pre-release 
testing: 
qualitative results 
on DBS
Conventional Real-time Total results 
n = 33 
n(%)
SAMPLE Target sample con-
centration (copies/ml)
MI1 UT12 UT22 In-house n = 5 n 
(%)
Commercial n = 
5 n (%)
In-house n = 23 n 
(%)
A3 . 9  ×  1 0 6 + + + 5 (100.0) 5 (100.0) 23 (100.0) 33 (100.0)
B9 . 6  ×  1 0 5 + + + 5 (100.0) 5 (100.0) 22 (95.7) 32 (97.0)
C8 . 8  ×  1 0 4 + + + 5 (100.0) 5 (100.0) 20 (87.0) 30 (90.9)
D9 . 4  ×  1 0 3 + + + 5 (100.0) 5 (100.0) 10 (43.5) 20 (60.6)
E9 . 4  ×  1 0 3 + - + 5 (100.0) 5 (100.0) 9 (39.1) 19 (57.6)
F7 . 3  ×  1 0 2 - - + 2 (40.0) 2 (40.0) 2 (8.7) 6 (18.2)
G7 . 3  ×  1 0 2 - - - 0 (0.0) 1 (20.0) 1 (4.3) 2 (6.1)
H negative - - - 4 (80.0) 5 (100.0) 22 (95.7) 31 (93.9)
I negative - - - 4 (80.0) 4 (80.0) 22 (95.7) 30 (90.9)
1 Nested PCR in-house on the Applied Biosystems (ABI) GeneAmp PCR System 9700. Sample pre-treatment: thermal shock (Binda et al 2004). 
Analysis of one punch (3 mm) in triplicate.
2 Real-time in house PCR on the Applied Biosystems (ABI) ABI PRISM 7900 Sequence Detection System. Sample pre-treatment: QIAGEN DSP kit. 
UT1: Analysis of three punches (3 mm each), UT2: Analysis of the entire dried blood spot.BMC Microbiology 2008, 8:2 http://www.biomedcentral.com/1471-2180/8/2
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points. On average, in house real-time PCR performed less
well than conventional PCR and commercial real-time
PCR. In fact the mean score attained by the former tech-
nology was 11.4 ± 2.7 versus 14.0 ± 1.4 and 14.8 ± 1.1 of
the latter methods, respectively. These differences were
statistically not significant.
The results of this first external quality assessment study
indicate that methods should be improved in order to
achieve better rates of sensitivity and specificity.
A previous study [5] showed that the median viral load in
the cord blood of congenitally infected babies is 2.4 × 103
copies/ml. Thus our study indicates that over 50% of lab-
oratories would not be able to identify congenitally
infected babies by analysis of DBS. Only a few laborato-
ries were able to detect a viral load of 7.3 × 102 copies/ml;
the fact that half of these laboratories also reported false-
positive results compromises the reliability of their
results.
False positivity involved 9% of laboratories and 11% of
datasets. This strongly affects the reliability of the retroac-
tive congenital CMV diagnosis because of the impossibil-
ity of confirming the positive results through the classical
CMV isolation assay on neonatal urine sample.
Lack of adherence to strict measures aimed at avoiding
contamination and carry-over are the most probable
cause of false positive results.
Testing CMV DNA on DBS presents several critical points.
The methods of elution and extraction of DNA, the
amount of spotted paper, the characteristics of the indi-
vidual PCR tests and the criteria for positivity all can affect
the performance of the test [2]. In this study we consid-
ered only the PCR methodology as assessment of the con-
tribution of the various variables was not the intention of
the study. Also, the number of laboratories using the same
or similar protocols were too small for such an analysis.
Conclusion
The importance of CMV-DNA detection on DBS relies on
the peculiarity of the sample which is routinely collected
in many countries and can be safely stored for years. In the
field of congenital infection diagnosis and epidemiology
it can be used to assess the prevalence of the infection in
large population groups, to conduct neonatal screenings
aimed at identifying and treating children at risk of per-
manent sequelae because of the infection, and to evaluate
the burden of the infection as a cause of permanent dam-
age.
The results of this first external quality assessment study
indicate a clear need for improvement of methods. Future
quality assessment programs should collect more detailed
data on all the critical points of the assay. The results of
such further quality assessment studies will aid laborato-
ries in adjusting the assay in order to achieve better rates
of sensitivity and specificity and to fully exploit the test.
Methods
Panel
Each participating laboratory received a panel consisting
of nine samples with two blood spots on filter paper (903
Whatman) each (Table 1) and a questionnaire on the
applied methods. One sample (A) was a CMV positive
clinical specimen, six samples (B-G) were derived from
whole blood, negative for CMV-DNA and antibody, and
spiked with cell-grown CMV Towne diluted tenfold to var-
ious concentrations. The same CMV-negative whole
blood was used for the negative controls (H-I). Both the
CMV-negative blood and the clinical specimen were col-
lected with EDTA as anti-coagulant. Each spot was pre-
pared with 40 microlitres of sample. Materials were sent
to laboratories in aluminium-coated envelopes by courier
service at room temperature. Laboratories were given six
weeks to return their results and the technical question-
naire to QCMD's Neutral Office in Glasgow.
Pre-distribution testing
Samples were tested prior to dispensing on the cards. Tar-
get sample concentrations were determined by means of a
commercial real-time PCR system (Nanogen Advanced
Diagnostics srl Q-CMV Real-time Complete Kit) on the
ABI 7300 Real-time PCR System (Applied Biosystem).
Pre-release testing was performed on the panel by two
independent laboratories using nested or real-time in-
house PCR assays (Table 1).
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